RxDoctor Payments Data

Jin Zhang, DO

Family Medicine · Flushing, NYNPI 1497026553

Payments from drug & device makers

$1,648in general payments, 2019–2025

Across 33 payments — averaging $49.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$297
  • Axsome Therapeutics, Inc.$263
  • AbbVie$180
  • AstraZeneca$159
  • Johnson & Johnson$156
  • Amgen$105
  • plus $488 from 13 others

What the payments were for

  • Food & beverage$1,648100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,648 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$26,113
Medicare patients
44
Services billed
341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$18,081
JanuviaSitagliptin Phosphate12$17,708
JardianceEmpagliflozin12$15,225
VascepaIcosapent Ethyl35$10,966
Diclofenac Epolamine12$6,615
Clobetasol Propionate13$2,790
Omega-3 Acid Ethyl Esters19$2,433
Atorvastatin Calcium246$2,045
PaxlovidNirmatrelvir/Ritonavir11$1,301
SynthroidLevothyroxine Sodium11$1,090
Tamsulosin Hcl52$773
Losartan Potassium104$729
Amlodipine Besylate124$729
FenofibrateFenofibrate Nanocrystallized18$656
Betamethasone Dipropionate13$611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$297$18,08111 claims
PfizerPaxlovid$50$1,30111 claims
AbbVieSynthroid$180$1,09011 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$47$40516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →